DT Form 144 Filed for 7,506-Share Sale; Broker Morgan Stanley Listed
Rhea-AI Filing Summary
Dynatrace, Inc. (DT) Form 144 notifies a proposed sale of 7,506 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $373,306.41, and an approximate sale date of 09/09/2025. The filing lists 301,506,242 shares outstanding. The shares to be sold were acquired on 09/05/2025 as 4,651 performance shares and 2,855 restricted stock. The filing also discloses a prior sale by Daniel J. Zugelder of 15,822 shares on 07/01/2025 for $867,702.21. The filer certifies they are not aware of any undisclosed material adverse information about the issuer.
Positive
- Transaction disclosed under Rule 144, indicating regulatory compliance
Negative
- None.
Insights
TL;DR Routine insider notice of proposed sale; disclosed acquisition dates and a recent larger sale are provided.
The Form 144 details a small proposed disposition relative to the issuer's outstanding shares: 7,506 shares versus 301,506,242 outstanding. The filing records that the securities were awarded on 09/05/2025 as performance shares and restricted stock, indicating these are insider compensation-related disposals rather than open-market purchases. The filing also reports a prior sale of 15,822 shares on 07/01/2025 for $867,702.21, which is documented for aggregation purposes. Overall this is a compliance disclosure under Rule 144 without standalone financial metrics or forward-looking statements.
TL;DR Compliance-focused disclosure showing insider sales tied to compensation vesting; no material nonpublic information asserted.
The notice includes required representations about material information and references possible reliance on trading plans. The timing—acquisition on 09/05/2025 and proposed sale on 09/09/2025—suggests vesting-triggered sales. Disclosure of the broker and exact aggregate market value meets regulatory transparency expectations. There are no allegations or indicators of governance issues in the text; the form is procedural and aimed at regulatory compliance.